Could zinc oxide tetrapod nanoparticles be used as an effective immunotherapy against HSV-2?

Herpes simplex virus (HSV) is a very common virus affecting a large section of the human population worldwide. Two serotypes of the virus, HSV-1 and HSV-2, cause ocular/facial and genital infections, respectively, which can result in recurrent symptomatic health problems in a significant number of healthy as well immunocompromised individuals. It is estimated that symptomatic oral and genital herpes infections affect 30% of the human population [1]. An estimated $984 million annual direct medical cost is endured in USA alone with an additional $214 million indirect costs spent on managing the disease-related issues [2].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please Login or Register to view this area.